Advaxis (Advaxis) GF Value Rank : 0 (As of Apr. 28, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Advaxis GF Value Rank?

Advaxis has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Advaxis GF Value Rank Related Terms

Thank you for viewing the detailed overview of Advaxis's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Advaxis (Advaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540

Website

https://www.advaxis.com

Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.

Executives

Roy Golan	officer: Chief Financial Officer	24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly	director	C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach	director	C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell	director	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg	director	2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib	director	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel	10 percent owner	YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman	officer: Chief Accounting Officer	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070